Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03523091 · ClinicalTrials.gov registry record · Phase 4
OnabotulinumtoxinA Bladder Injection Study
A Phase 4 study, sponsored by Corewell Health East.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT03523091 is a Phase 4 study that was terminated before completion, run by Corewell Health East. The registered enrollment target is 6 participants.
The verdict
NCT03523091, a Phase 4 study, was terminated before completion, sponsored by Corewell Health East.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
Patients with overactive bladder (OAB) will be randomly assigned (like a flip of a coin) to receive 100 units of onabotulinumtoxinA injected into the bladder at either 3 sites or 10 sites. Patient satisfaction and the effectiveness of the medication will be evaluated.
Interventions
- DRUG OnabotulinumtoxinA 100Unit Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-08-08 |
| Est. Completion | 2020-09-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03523091
The ClinicalTrials.gov registry entry for NCT03523091 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health East, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OnabotulinumtoxinA 100Unit Injection is the first listed.
NCT03523091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03523091 about?
NCT03523091 is a clinical study titled "OnabotulinumtoxinA Bladder Injection Study". Patients with overactive bladder (OAB) will be randomly assigned (like a flip of a coin) to receive 100 units of onabotulinumtoxinA injected into the bladder at either 3 sites or 10 sites. Patient satisfaction and the effectiveness of the medication will be evaluated.
What is the current status of trial NCT03523091?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2018-08-08. Estimated completion is 2020-09-01.
What interventions are being tested in trial NCT03523091?
The interventions under investigation include: OnabotulinumtoxinA 100Unit Injection (DRUG).
Who is sponsoring clinical trial NCT03523091?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.